MESO Archives - BioTuesdays

Developments

FDA approval of Mesoblast’s RYONCIL bodes well for other cell therapy companies like BioRestorative Therapies and Cell Technologies

Mesoblast (ASX:MSB; NASDAQ:MESO) is rallying today after the company announced yesterday after market close that the FDA approved RYONCIL (remestemcel-L), an allogeneic (donor) bone marrow-derived mesenchymal stromal...

December 19, 2024

Developments

Mesoblast receives FDA complete response for BLA in GvHD

Mesoblast (NASDAQ:MESO, ASX:MSB) received a complete response letter to its biologics license application resubmission for remestemcel-L for the treatment of pediatric steroid-refractory acute graft versus host disease...

August 4, 2023

Markets

WB starts Mesoblast at OP; fair value estimate $8

William Blair initiated coverage of Mesoblast (NASDAQ:MESO) with an “outperform” rating and fair value estimate of $8. The stock closed at $3.03 on March 8. Mesoblast is developing mesenchymal lineage cell-derived...

March 9, 2023

Markets

Dawson James cuts Mesoblast to neutral on potential capital raise

Dawson James downgraded Mesoblast (NASDAQ:MESO; ASX:MSB) to “neutral” and removed its price target after the stock was halted on Aug. 4 in Australia with news of a proposed private placement and another notice of a halt...

August 8, 2022

Markets

Dawson James cuts Mesoblast PT despite encouraging heart data

Dawson James lowered its price target for Mesoblast (NASDAQ:MESO) to $7 from $12, but retained its “buy” rating, after the company reported encouraging data from a 565-patient trial in New York Heart Association Class...

July 19, 2022

Markets

Maxim ups Mesoblast to buy from hold; PT $18

Maxim Group upgraded Mesoblast (NASDAQ:MESO) to “buy” from “hold” with a price target of $18, citing the totality of the company’s cell therapy data, which are “quite good.” The stock closed at $8.45 on April 6...

April 7, 2021

Developments

Mesoblast cell therapy posts 83% survival in COVID-19 ARDS patients

Mesoblast (NASDAQ:MESO; ASX:MSB) reported an 83% survival in 10-of-12, or 83%, of ventilator-dependent COVID-19 patients with moderate/severe acute respiratory distress syndrome (ARDS) treated during March-April 2020...

April 24, 2020

Developments

FDA clears Mesoblast IND for remestemcel-L in ARDS caused by COVID-19

Mesoblast (NASDAQ:MESO; ASX:MSB) received clearance from the FDA for an IND application to treat patients with acute respiratory distress syndrome (ARDS) caused by COVID-19 with intravenous infusions of its allogeneic...

April 6, 2020

Developments

FDA accepts Mesoblast BLA for RYONCIL; agrees to priority review

The FDA accepted for priority review Mesoblast’s (NASDAQ:MESO; ASX:MSB) biologics license application filing for RYONCIL, its allogeneic cell therapy for the treatment of children with steroid-refractory acute graft...

April 1, 2020

Developments

Mesoblast submits completed BLA for Ryoncil to FDA

Mesoblast (NASDAQ:MESO; ASX:MSB) submitted its completed biologics license application (BLA) to the FDA for Ryoncil, its lead allogeneic cell therapy for the treatment of children with steroid-refractory acute graft...

February 3, 2020

Tag - MESO

FDA approval of Mesoblast’s RYONCIL bodes well for other cell therapy companies like BioRestorative Therapies and Cell Technologies

Mesoblast receives FDA complete response for BLA in GvHD

WB starts Mesoblast at OP; fair value estimate $8

Dawson James cuts Mesoblast to neutral on potential capital raise

Dawson James cuts Mesoblast PT despite encouraging heart data

Maxim ups Mesoblast to buy from hold; PT $18

Mesoblast cell therapy posts 83% survival in COVID-19 ARDS patients

FDA clears Mesoblast IND for remestemcel-L in ARDS caused by COVID-19

FDA accepts Mesoblast BLA for RYONCIL; agrees to priority review

Mesoblast submits completed BLA for Ryoncil to FDA

General

More